Williams Richard
Geriatrics, Edward Via College of Osteopathic Medicine, Blacksburg, USA.
Cureus. 2025 Jan 9;17(1):e77188. doi: 10.7759/cureus.77188. eCollection 2025 Jan.
The initial COVID-19 infection caused significant mortality in the nursing home setting. The mortality in our facility was approximately 50% and occurred in the later phase of the initial infection. In the nursing home setting, there were no approved treatment regimes. Specific treatment was left to the treating physician in concert with the administrative medical officials; immunizations were approved in December 2020. Concurrent publications indicated that epigallocatechin gallate (EGCG) and humic/fulvic acid with vitamin C possess the ability to interfere with the SARS-CoV-2 virus; both can inhibit viral attachment and reproduction, along with providing significant anti-inflammatory activity. They also exhibit good safety profiles and were previously utilized in our facility. With the high mortality and significant published data on inhibitory aspects of EGCG, humic/fulvic acid, and vitamin C, our facility utilized these supplements to treat COVID-19-positive patients.
This retrospective chart review analyzes the effectiveness of an integrative treatment consisting of EGCG and humic/fulvic acid with vitamin C provided to COVID-19 patients in a long-term care facility between October and December 2020. Nursing home patients with COVID-19 infections were either provided integrative treatment utilizing EGCG, humic/fulvic acid, and vitamin C or provided care without integrative support. All EGCG patients were informed, and, when needed, the first line of authority, power of attorney (POA) was contacted and informed that the integrative approach was not standard treatment (but was reviewed and approved by Pulaski Health and Rehabilitation Medical Facility directors and the patient's physician). Patients were informed of the safety literature and compounds' utilization in viral infections prior to accepting treatment.
A review of 60 records indicates that among 22 patients receiving treatment with the integrative combination, there were no mortalities. Among 38 patients treated without this integrative support, there were 21 deaths. Conclusions: In a retrospective review of the treatment data, treatment of COVID-19 in the nursing home setting with EGCG, humic/fulvic acid, and vitamin C resulted in a significant reduction in overall mortality.
最初的新型冠状病毒肺炎(COVID-19)感染在养老院环境中导致了显著的死亡率。我们机构的死亡率约为50%,且发生在初始感染的后期。在养老院环境中,没有获批的治疗方案。具体治疗由主治医生与行政医疗官员共同决定;2020年12月批准了免疫接种。同期发表的文献表明,表没食子儿茶素没食子酸酯(EGCG)以及含有维生素C的腐殖酸/富里酸具有干扰严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒的能力;二者均可抑制病毒附着和繁殖,并具有显著的抗炎活性。它们还具有良好的安全性,且此前已在我们机构使用。鉴于EGCG、腐殖酸/富里酸和维生素C在抑制方面的高死亡率和大量已发表数据,我们机构使用这些补充剂来治疗COVID-19阳性患者。
本回顾性病历审查分析了2020年10月至12月期间在一家长期护理机构中为COVID-19患者提供的由EGCG、腐殖酸/富里酸和维生素C组成的综合治疗的有效性。患有COVID-19感染的养老院患者要么接受了使用EGCG、腐殖酸/富里酸和维生素C的综合治疗,要么在没有综合支持的情况下接受护理。所有接受EGCG治疗的患者均被告知,如有需要,会联系第一授权人,即委托代理人(POA)并告知其综合治疗方法并非标准治疗(但已由普拉斯基健康与康复医疗设施主任及患者的医生审查并批准)。在患者接受治疗前,会告知他们关于安全性文献以及这些化合物在病毒感染中的使用情况。
对60份记录的审查表明,在接受综合联合治疗的22名患者中,无死亡病例。在未接受这种综合支持治疗的38名患者中,有21人死亡。结论:在对治疗数据的回顾性分析中,在养老院环境中使用EGCG、腐殖酸/富里酸和维生素C治疗COVID-19可显著降低总体死亡率。